Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615511 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Pregnenolone in Patients With Schizophrenia
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00615511: Completed Phase 2 study, sponsored by Weill Medical College of Cornell University.
NCT00615511 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00615511, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Four-month trial of pregnenolone or placebo, as an additional medication, to treat negative symptoms and cognitive decline in schizophrenia. After four months the scores on the negative symptom scale should be lower and the scores on the cognitive tests should be higher than they were at study entry, compared with people who do not take any additional medication.
Interventions
- DIETARY_SUPPLEMENT pregnenolone
- DIETARY_SUPPLEMENT placebo pregnenolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
What the finished NCT00615511 record still lists
NCT00615511 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 2 interventions - of which pregnenolone is the first listed.
NCT00615511 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00615511 about?
NCT00615511 is a clinical study titled "Efficacy of Pregnenolone in Patients With Schizophrenia". Four-month trial of pregnenolone or placebo, as an additional medication, to treat negative symptoms and cognitive decline in schizophrenia. After four months the scores on the negative symptom scale should be lower and the scores on the cognitive tests should be higher than they were at study entry...
What is the current status of trial NCT00615511?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2007-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00615511?
The interventions under investigation include: pregnenolone (DIETARY_SUPPLEMENT), placebo pregnenolone (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00615511?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00615511's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia